<a href=Novartis AG” class=”halfleft” src=”https://www.drugdevelopment-technology.com/wp-content/uploads/image-digitalinsightresearch/Archive/nri/Drug%20development/News/May%2027/Novartis_Drug%20Deals_Novartis.jpg” />

TriNetX and Celgene have entered a partnership to further develop clinical trial design and research for next-generation medicines.

According to the agreement, Celgene will use TriNetX’s proprietary network of healthcare institutions to gain access to medical data from electronic medical records of more than 37 million patients under clinical study and protocol design, site selection, and patient recruitment data across a range of therapeutic areas and development stages.

Astellas Pharma, Daiichi Sankyo and Takeda pharmaceutical have entered a co-development agreement for the optimisation and acceleration of the innovative research and drug discovery in Japan.

According to the agreement, the companies will collect the basic data required for the clinical studies from healthy adult volunteers using protein and metabolite biomarkers from a clinical research organisation associated with Leiden University in the Netherlands.

Further analysis will be jointly performed by the three companies. The results of the analysis will be utilised in the companies’ specific therapeutic areas in order to support various drug discoveries and to meet the patient’s needs.

Noden Pharma DAC, a specialty pharmaceutical company, has announced that it will further develop its cardiovascular product line by acquiring the worldwide rights of Tekturna (aliskiren) and Tekturna HCT (aliskiren and hydrochlorothiazide) from Novartis AG through the funds raised from a private placement of its shares.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company expects to raise gross proceeds of approximately $107m from the placement.

It has further announced to acquire worldwide rights to manufacture, market and sell the prescription medicines sold under the brand names Tekturna and Tekturna HCT in the US and Rasilez and Rasilez HCT in the rest of the world.

Albertsons Companies has announced that it will raise $1.25bn by offering senior notes due in 2024.

"The company expects to raise gross proceeds of approximately $107m from the placement."

The company plans to use the funds raised to pay the redemption price and accrued and unpaid interest in connection with the redemption of all the outstanding 7.75% senior secured notes due 2022.

It has further announced that Albertson Companies and its subsidiaries, Safeway Inc, New Albertson’s Inc and Albertson’ LLC, will be the co-issuers of the notes.

Relief Therapeutics plans to begin its Phase II randomised, placebo-controlled, multi-centre study to evaluate the safety and efficacy of atexakin alfa in diabetic neuropathy through the funds raised from a series A financing round.

The company has raised $2.8m from the financing round, which was led by Global Emerging Markets.

Image : Noden Pharma DAC will acquire worldwide rights of Tekturna (aliskiren) and Tekturna HCT (aliskiren and hydrochlorothiazide) from Novartis AG. Photo : Courtesy of Novartis AG.